Apotex Generic Semaglutide Pen: Lot 7000636A Recalled Over Dose Display

The recall in brief

Apotex recalled lot 7000636A of its generic semaglutide (Apo-Semaglutide) 1 mg-dose pen on September 23, 2026. Health Canada says affected pens may show and deliver 0.25 mg or 0.5 mg when the dose window should read 1 mg.

• Product: Apo-Semaglutide injection, 1 mg-dose pen (4 mg/pen), DIN 02568012, 1.34 mg/mL
• Affected lot: 7000636A
• Recall date: September 23, 2026 (Health Canada reference RA-82679, Type II, retail depth)
• Distribution: Alberta, British Columbia, Manitoba, New Brunswick, Newfoundland and Labrador, Ontario and Quebec

How to check

The lot number is printed on the pen and on the carton. If yours does not read 7000636A, this recall does not apply to your pen. If it does, do not stop on your own: call your pharmacist or prescriber, and direct questions about the recall to Apotex. Side effects can be reported to Health Canada.

Same molecule, different device

The recall concerns a pen's dose display, not the semaglutide inside it. Ozempic and Wegovy use different pens made by Novo Nordisk, and Health Canada's notice does not name them. A generic and a brand-name pen contain the same active ingredient, but the device, the dose steps and the price differ, which is why we track them separately.